Citizens JMP raised the firm’s price target on MBX Biosciences (MBX) to $61 from $38 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz
- MBX Biosciences price target raised to $80 from $38 at Oppenheimer
- MBX Biosciences Stock Rockets on Clinical Trial Update
- Morning Movers: Metsera surges, Pfizer gains after acquisition pact
- Video: Metsera jumps after Pfizer strikes deal for obesity drugmaker